Dynavax 是一家美国公司. 我认为不是DNA. "combines both the surface and core hepatitis B virus (HBV) antigens" - 结合了表面和核心乙型肝炎病毒（HBV）的抗原.
下面是从该公司的发言:
Hepatitis B Therapy
Our hepatitis B therapy, DV-601, is currently in phase 1b clinical development. This novel treatment approach, which for the first time combines both the surface and core hepatitis B virus (HBV) antigens, may offer a more effective therapeutic option for patients chronically infected with HBV. We have retained all commercial rights to this product.
Commercial Opportunity
Over 350 million individuals worldwide are chronically infected with HBV, which can lead to cirrhosis of the liver and liver cancer. The current worldwide market for HBV therapeutics is estimated to be over $1 billion annually and available therapies have modest efficacy.
Our HBV therapy, used in combination with existing antiviral therapies, is expected to induce a potent immune response against HBV-infected cells in the liver to eradicate HBV infection and may offer a more effective therapeutic option for chronically infected patients.
